At Janssen, we are committed to helping people living with HIV in resource-limited settings by ensuring effective and sustainable access to our HIV medicines, or antiretrovirals (ARVs). We believe that effective HIV drug access has two important components: ensuring quality and affordable medicines are available sustainably and that they are used safely and in the most appropriate way for people living with HIV/AIDS (PLWHA).
Through our comprehensive HIV drug access framework (Read our Framework PDF), our Janssen Global Public Health HIV Medicines Access & Partnerships Program works to fulfill our responsibility to provide access to our medicines, specifically in least-developed countries and lower middle-income countries (LDCs and LMICs). The program includes:
- Operating on a sustainable, not-for-profit basis in LDCs and LMICs (Read our Special Access Pricing for Branded HIV Medicines PDF)
- Licensing for both branded and generic versions of our HIV medicines (Read our Licensing PDF)
- Prioritizing regulatory filings where there is a public health need (Read our Branded Registration Efforts PDF)
- Supporting the optimal, appropriate and safe use of our HIV medicines (Read our Optimizing Use of Our HIV Medicines in Resource-Limited Countries PDF)
We invite you to learn more by viewing the Jannsen Global Public Health HIV Medicines Access & Partnerships Program Overview: HIV Medicine Access brochure (PDF).